Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 9;388(6):567-569.
doi: 10.1056/NEJMc2213907. Epub 2023 Jan 11.

Antibody Response to Omicron BA.4-BA.5 Bivalent Booster

Affiliations

Antibody Response to Omicron BA.4-BA.5 Bivalent Booster

Qian Wang et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Neutralization Profiles of Serum Samples against SARS-CoV-2 Variants and Other Sarbecoviruses.
Panel A shows the 50% inhibitory dilution (ID50) titers of serum samples obtained from participants who had received either three or four doses of a monovalent messenger RNA (mRNA) vaccine (three-dose and four-dose monovalent groups), those who had BA.4–BA.5 breakthrough infection after three or four doses of monovalent mRNA vaccine (convalescent group), and those who had received three doses of a monovalent mRNA vaccine followed by one dose of a bivalent vaccine targeting BA.4–BA.5 variants (bivalent-booster group). Panel B shows the antibody response induced by a fourth dose of the original monovalent mRNA vaccine as compared with a fourth dose of a BA.4–BA.5 bivalent booster. Fourth doses of the mRNA-1273 vaccines are indicated by bold symbols; nonbold symbols indicate fourth doses of the BNT162b2 vaccines. Between-group comparisons were performed with the use of Mann–Whitney tests. In Panels A and B, values above the data points indicate the geometric mean ID50 titers, the dotted horizontal lines indicate the lower limit of detection of the assay, and 𝙸 bars indicate the standard deviation.

References

    1. Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 2022;608:603-608. - PMC - PubMed
    1. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes Moderna, Pfizer-BioNTech bivalent COVID-19 vaccines for use as a booster dose. August 31, 2022. (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19...).
    1. Chalkias S, Harper C, Vrbicky K, et al. A bivalent omicron-containing booster vaccine against Covid-19. N Engl J Med 2022;387:1279-1291. - PMC - PubMed
    1. Scheaffer SM, Lee D, Whitener B, et al. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 omicron variant in mice. Nat Med 2022. October 20 (Epub ahead of print). - PMC - PubMed
    1. Wheatley AK, Fox A, Tan H-X, et al. Immune imprinting and SARS-CoV-2 vaccine design. Trends Immunol 2021;42:956-959. - PMC - PubMed

Publication types

Supplementary concepts